Researchers have discovered that changes in monocytes (a type of white blood cell) are a biomarker for amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease. This finding could lead to a new treatment for the debilitating neurological disease, which affects approximately 30,000 Americans.
Articles from August 2012
“This study shows that cytoskeletal defects can lead to ALS, and tell us that we should be looking closer at these pathways in the development of disease.”
Researchers in Japan have pinpointed a protein which could slow the development of amyotrophic lateral sclerosis (ALS), a degenerative disease of the nerve cells that gradually causes muscle weakness and atrophy.
Chaim Lebovits, CEO and president of BrainStorm Cell Therapeutics in Israel, discusses the potential for the company’s developmental therapy and its implications for patients with ALS. He is joined in this segment by Rasheda Ali, daughter of Muhammad Ali, and an advisory board member for BrainStorm.
Dramatic Change in Patient with ALS and MG following Compassionate Use of BrainStorm’s NurOwn™ Cell Therapy
“We are moved by the remarkable results observed following treatment with NurOwn,” said Professor Avi Israeli, BrainStorm’s Chairman of the Board. “We are hopeful that we will continue to see this kind of improvement in all the patients participating in our current and future clinical trials.”